Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MDxHealth (MDXH) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for MDxHealth (MDXH) over the last 4 years, with Q3 2025 value amounting to -$1.7 million.

  • MDxHealth's Cash from Financing Activities fell 10501.28% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 8742.97%. This contributed to the annual value of $44.6 million for FY2024, which is 3815.99% up from last year.
  • As of Q3 2025, MDxHealth's Cash from Financing Activities stood at -$1.7 million, which was down 10501.28% from -$11.7 million recorded in Q2 2025.
  • In the past 5 years, MDxHealth's Cash from Financing Activities ranged from a high of $39.7 million in Q4 2021 and a low of -$11.7 million during Q2 2025
  • For the 4-year period, MDxHealth's Cash from Financing Activities averaged around $8.9 million, with its median value being -$459000.0 (2021).
  • Data for MDxHealth's Cash from Financing Activities shows a peak YoY increase of 10501.28% (in 2025) and a maximum YoY decrease of 10501.28% (in 2025) over the last 5 years.
  • MDxHealth's Cash from Financing Activities (Quarter) stood at $39.7 million in 2021, then tumbled by 102.01% to -$799000.0 in 2022, then surged by 210.64% to $884000.0 in 2024, then tumbled by 290.27% to -$1.7 million in 2025.
  • Its Cash from Financing Activities stands at -$1.7 million for Q3 2025, versus -$11.7 million for Q2 2025 and $21.5 million for Q1 2025.